Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists
Provided By GlobeNewswire
Last update: Apr 1, 2025
Appointment of seven recognized experts is validating for Ventyx’s NLRP3 Program
--
AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson’s disease
